We need more clinical evidence, especially large trials with gout patients using standard measurements
63 A case series linked the use of semaglutide or tirzepatide with an increased risk of NAION, sometimes after a single dose, including in one patient without diabetes and in another who experienced symptoms in both eyes following separate doses
As we continue to add more medications that improve outcomes for patients with diabetic kidney disease, we will need to decide how we go about giving patients these medications, and we will need further trials to determine if there are benefits to being treated with as many kidney-protective medications as there are to offerSGLT2is, renin angiotensin system inhibitors, mineralocorticoid receptor antagonists, and now GLP-1 receptor agonists
Interestingly, a study conducted by the Petterson group revealed that C57BL/6 J mice displayed reduced locomotor activity in adulthood 59
So far, research does not show a strong link between semaglutide and orthostatic hypotension
